OPIOID DEPENDENCE IS A TREATABLE DISEASE.

The criminal justice system is challenged with responding to the opioid epidemic.

Intervention opportunities, like medication-assisted treatment, may exist in the criminal justice system for appropriate individuals with opioid dependence. However, medication-assisted treatment is underused despite its effectiveness.

VIVITROL® (naltrexone for extended-release injectable suspension) is a non-addictive, once-monthly treatment option. After detox and when combined with counseling, it has been proven to prevent relapse to opioid dependence. VIVITROL is an HCP-administered treatment that is not associated with diversion.

Prior to the initiation of VIVITROL, patients should be opioid-free for a minimum of 7-10 days to avoid precipitation of opioid withdrawal that may be severe enough to require hospitalization.

IMPORTANT SAFETY INFORMATION:

INDICATIONS

VIVITROL is indicated for:
- Treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to the initiation of treatment with VIVITROL.
- Prevention of relapse to opioid dependence, following opioid detoxification.
- VIVITROL should be part of a comprehensive management program that includes psychosocial support.

CONTRAINDICATIONS

VIVITROL is contraindicated in patients:
- With current physiologic opioid dependence
- In acute opioid withdrawal
- Who have failed the naltrexone challenge test or have a positive urine screen for opioids
- Who have exhibited hypersensitivity to naltrexone, polyactide-co-glycolide (PLG), carbomethylcellulose, or any other components of the diluent

For additional Important Safety Information, please see the Brief Summary of Prescribing Information on adjacent pages.